Literature DB >> 15651796

A study of vinyl radical cyclization using N-alkenyl-7-bromo-substituted hexahydroindolinones.

Albert Padwa1, Paitoon Rashatasakhon, Ayse Daut Ozdemir, Jerremey Willis.   

Abstract

A new method for the synthesis of the octahydropyrrolo[3,2,1-ij]quinoline ring system that possesses the characteristic skeleton of the aspidosperma family of alkaloids has been developed. The method utilizes an intramolecular Diels-Alder reaction of an amido-substituted furan across a tethered indole pi-bond. To apply this strategy to the synthesis of the indole alkaloid spegazzinidine, it was necessary to address the problem of assembling the final D-ring of the pentacyclic skeleton. Radical cyclization of a model N-allyl-7-bromo-3a-methylhexahydroindolinone system was found to preferentially lead to the 6-endo-trig cyclization product, with the best yield being obtained under high dilution conditions. The six-membered cyclized product is generated through two reaction pathways: (a) 6-endo-trig ring closure and (b) rearrangement of an intermediate methylene-cyclopentyl radical obtained by 5-exo-trig cyclization. A number of related 7-bromo-substituted hexahydroindolinones containing tethered olefinic groups were prepared and found to undergo efficient cyclization under both radical and palladium-mediated reaction conditions. Vinyl radical cyclization with several N-butenyl-substituted systems afforded a mixture of 6-exo and 7-endo cyclization products. A protocol to introduce an ethyl substituent into the C20-position of the aspidospermidine skeleton was also developed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15651796     DOI: 10.1021/jo048314i

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  1 in total

1.  Synthetic progress toward the marine natural product zamamiphidin A.

Authors:  Hao Wang; Di Tian; Zhaoxiang Meng; Zhihao Chen; Fei Xue; Xiao-Yu Liu; Hao Song; Yong Qin
Journal:  RSC Adv       Date:  2020-03-24       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.